Psilocybin

—

evidence score

other

Scheduled Substance

magic mushroomspsilocin (active metabolite)4-PO-DMT+2 more

Psilocybin is a naturally occurring tryptamine prodrug found in over 200 mushroom species. It is dephosphorylated to psilocin in vivo, which acts as a 5-HT2A agonist. The most significant development in psychiatry in decades: FDA Breakthrough Therapy designation for treatment-resistant depression (2018) and major depressive disorder (2019). Phase 3 trials show 1-2 doses produce rapid (within weeks), sustained (6-12 months) remission of treatment-resistant depression. MAPS and Compass Pathways Phase 3 trials running. Microdosing (sub-perceptual doses) is a growing area with mixed clinical data but significant anecdotal use in tech/performance communities. Oregon and Colorado have state-level regulated medical frameworks as of 2024.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Dosing

Typical

25 mg

1 mgRange40 mg

Frequencysingle session or every 2-4 weeks (therapeutic); 0.1-0.3mg every 3 days (microdosing)

Set height & weight in Settings to see your dose.

Pharmacology

Half-lifePsilocin: ~3 hours; psychological effects 4-6 hours

OnsetPsychedelic effects 30-60 min; antidepressant effects within days to weeks after single session

DurationAcute: 4-6 hours; therapeutic antidepressant effects: months from single dose

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(24%)—

Quality(24%)—

Sample Size(12%)—

Consistency(14%)—

Replication(8%)—

Recency(18%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Psilocybin is currently categorized as a other compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

5-HT2A full agonist in PFC, DMN, and limbic system; increases synaptic density (rapid, AMPA-mediated); Default Mode Network (DMN) disruption; neuroplasticity via BDNF and TRKB

Practical Context

Strongest current signals

No indexed study summaries yet.

Elevated caution signals

2 severe/high side effect flags